CHMP adopts positive opinion of Edurant in adolescents with HIV-1

  • CHMP,HIV-1,Edurant,adolescents
  • Victoria White

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection, starting treatment for the first time and with a viral load ≤ 100,000 HIV-1 ribonucleic acid (RNA) copies/ml at start of treatment.


Edurant is already approved in Europe for the treatment of HIV-1 infection in combination with other antiretroviral agents in antiretroviral treatment-na?ve adult patients with a viral load ≤100,000 HIV RNA copies/mL. If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time. It is estimated that one in seven of all new HIV infections occur in adolescence and young adulthood.

CHMP opinion based on a Phase 2 study of Edurant in adolescents with HIV-1 infection

“In some regions, adolescents are an age group for whom HIV-related diseases are on the rise, as young people can be overlooked or face barriers when accessing health services. We are happy to be closer to improving the health needs of this vulnerable patient group,” said Christiane Moecklinghoff, M.D Ph.D., Medical Director, Virology, Janssen EMEA. “We look forward to the European Commission’s decision and the opportunity to offer an additional treatment option to adolescent patients.”

The CHMP adopted the opinion based on a review of 48-week data from a Phase 2 multi-centre study, which looked at the pharmacokinetics, safety/tolerability and efficacy of Edurant 25 mg once daily in combination with a background regimen of antiretroviral treatment in HIV-1 infected adolescents aged 12 to <18 years and starting treatment for the first time.

Updated results from the study showed that at week 48, 72% patients overall achieved virologic response (HIV-1 RNA < 50 copies/mL). Adverse events considered at least possibly related to Edurant occurred in 36% patients, mainly somnolence and nausea. Overall, the data support the use of Edurant combined with other antiretrovirals in adolescent patients aged 12 to <18 years with HIV-1 infection, starting treatment for the first time and who have a viral load ≤ 100,000 HIV-1 RNA copies/mL at start of treatment, with pharmacokinetic results similar to those observed in adults.

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA™ for use in the Treatment of Two Forms of Blood Cancer

2014/07/31 - Janssen-Cilag International NV (Janssen) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA?

First data backs efficacy of BMS' novel HIV drug

2015/10/30 - A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

Virus-killing molecules may need all their skills, including inflammation, to fight HIV infection

2014/07/28 - Using the body's natural virus killers to prevent and treat HIV infection has been problematic until now because of the strong inflammatory response these molecules can arouse as they get rid of the invaders.